Abstract
All four serotypes of dengue virus (DENV) cause the full spectrum of disease. Therefore, vaccines must protect against all serotypes. To evaluate candidate vaccines, a human challenge model of dengue serotype 3 (rDEN30Δ30) was developed. All challenge virus recipients safely met the primary endpoint of viremia and secondary endpoints of rash and seroconversion to DENV-3.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Clinicaltrials.gov NCT02684383.
Funding Statement
This work was supported by the National Institute of Allergy and Infectious Disease Intramural Research Program, National Institutes of Health [contract no. HHSN272200900010C]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted under IND application (IND # 16765) at the Center for Immunization Research, Johns Hopkins School of Public Health and the Vaccine Testing Center, University of Vermont College of Medicine, and was approved by their Institutional Review Boards and Biosafety Committees. The National Institute of Allergy and Infectious Diseases (NIAID) Intramural Data Safety Monitoring Board reviewed all study data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Errors in the submitted table were corrected. Corrections included the data in the 'viremia' column; the p-value for the adverse event 'induration'; and the addition of the adverse events 'photophobia', 'nausea', and 'hemoglobin decreased'.
Data Availability
All data produced in the present work are contained in the manuscript